Abstract
Objectives-Contrast-enhanced ultrasound (US) and targeted microbubbles have been shown to be advantageous for angiogenesis evaluation and disease staging in cancer. This study explored molecular US imaging of a multitargeted microbubble for assessing the early tumor response to antiangiogenic therapy. Methods-Targetreceptor expression of2LMPbreast cancer cellswasquantified by flow cytometric analysisandcharacterization established with antibodies againstmouseαVβ3- integrin, P-selectin, and vascular endothelial growth factor receptor 2. Tumor-bearing mice (n = 15 per group) underwent contrast-enhanced US imaging of multitargeted microbubbles. Microbubble accumulation was calculated by destruction-replenishment techniquesandtime-intensity curve analysis. On day 0, mice underwent baseline imaging. Next, therapy group mice were injected with a 0.2-mg dose of bevacizumab, and controls received matched saline injections. Imaging was repeated on days 1 and 3. After imaging was completed on day 3, the mice were euthanized and tumors excised. Histologic analysis of microvessel density and intratumoral necrosis was completed on tumor sections. Results-Onday 3 after bevacizumab dosing, a 71.8% change in tumor vasculaturewas shown between the therapy and control groups (P = .01). The therapy group had a 15.4% decrease in tumor vascularity, whereas the control group had a 56.4% increase. Conclusions- MolecularUSimaging of angiogenic markers can detect the early tumor response to drug therapy.
Original language | English (US) |
---|---|
Pages (from-to) | 1543-1550 |
Number of pages | 8 |
Journal | Journal of Ultrasound in Medicine |
Volume | 31 |
Issue number | 10 |
DOIs | |
State | Published - Oct 1 2012 |
Keywords
- Angiogenesis
- Antiangiogenic therapy
- Contrast-enhanced ultrasound
- Microbubbles
- Targeted contrast agent
ASJC Scopus subject areas
- Radiological and Ultrasound Technology
- Radiology Nuclear Medicine and imaging